Breast cancer (BC) is the most frequent cancer diagnosed in women worldwide. This
heterogeneous disease can be classified into four molecular subtypes (luminal A, luminal B …

BRCA1 and BRCA2 deficient tumor cells are sensitive to inhibitors of Poly ADP Ribose
Polymerase (PARP1) through the mechanism of synthetic lethality. Several PARP inhibitors …

Variants of uncertain significance fundamentally limit the clinical utility of genetic information.
The challenge they pose is epitomized by BRCA1, a tumour suppressor gene in which …

The tumour suppressor breast cancer type 1 susceptibility protein (BRCA1) promotes DNA
double-strand break (DSB) repair by homologous recombination and protects DNA …

Based on genomic analysis, 50% of high-grade serous ovarian cancers (HGSC) are
predicted to have DNA repair defects. Whether this substantial subset of HGSCs actually …

Homologous recombination (HR) repair deficiency impairs the proper maintenance of
genomic stability, thus rendering cancer cells vulnerable to loss or inhibition of DNA repair …

The cellular response to external stress signals and DNA damage depends on the activity of
ubiquitin ligases (E3s), which regulate numerous cellular processes, including homeostasis …

Approximately 50% of epithelial ovarian cancers (EOC) exhibit defective DNA repair via
homologous recombination (HR) due to genetic and epigenetic alterations of HR pathway …

Genetically engineered mouse models (GEMM s) have contributed significantly to the field of
cancer research. In contrast to cancer cell inoculation models, GEMM s develop de novo …

Homologous recombination (HR) is a major pathway for the repair of DNA double-strand
breaks in mammalian cells, the defining step of which is homologous strand exchange …